Literature DB >> 3005515

Collagenase activity in skin fibroblasts of patients with amyotrophic lateral sclerosis.

R L Beach, J S Rao, B W Festoff, E T Reyes, R Yanagihara, D C Gajdusek.   

Abstract

In the current study we have measured collagenase activity released from skin explants and fibroblasts of patients with both Guam-type and sporadic amyotrophic lateral sclerosis and controls. The rationale for such a study derives from work reported more than 20 years ago demonstrating abnormalities in skin collagen metabolism in patients with the disease. We were not able to find significant differences in collagenase activity when fibroblasts were compared relative to the total protein secreted. This is explained, in part, by our finding of an increase in total protein released from fibroblasts of the amyotrophic lateral sclerosis patient group. Increased collagenase release did occur when activity was expressed per number of cells plated but was not statistically significant. In addition, increased release followed a 3-day lag period in skin organ culture. These results suggest that collagenase and other enzymes known to activate collagenase, such as plasminogen activator, capable of degrading extracellular matrix components might be responsible for the increased collagenolytic activity previously observed in amyotrophic lateral sclerosis patients' skin. Further evaluation of extracellular-acting degradative enzymes from skin, muscle, nerve and central nervous system may be important to follow-up such leads in understanding the pathogenesis of this enigmatic and fatal disorder.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3005515     DOI: 10.1016/0022-510x(86)90035-3

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  4 in total

1.  Better understanding the neurobiology of primary lateral sclerosis.

Authors:  P Hande Ozdinler; Mukesh Gautam; Oge Gozutok; Csaba Konrad; Giovanni Manfredi; Estela Area Gomez; Hiroshi Mitsumoto; Marcella L Erb; Zheng Tian; Georg Haase
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2020-11       Impact factor: 4.092

Review 2.  Prospects for the pharmacotherapy of amyotrophic lateral sclerosis : old strategies and new paradigms for the third millennium.

Authors:  Barry W Festoff; Zhiming Suo; Bruce A Citron
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

3.  Association of skin with the pathogenesis and treatment of neurodegenerative amyloidosis.

Authors:  Audra L Clos; Rakez Kayed; Cristian A Lasagna-Reeves
Journal:  Front Neurol       Date:  2012-01-20       Impact factor: 4.003

4.  Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients.

Authors:  Csaba Konrad; Hibiki Kawamata; Kirsten G Bredvik; Andrea J Arreguin; Steven A Cajamarca; Jonathan C Hupf; John M Ravits; Timothy M Miller; Nicholas J Maragakis; Chadwick M Hales; Jonathan D Glass; Steven Gross; Hiroshi Mitsumoto; Giovanni Manfredi
Journal:  Mol Neurodegener       Date:  2017-10-24       Impact factor: 14.195

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.